Clinical Therapeutics

Editorial comment
pp. 2-3(2)
Author: Krosnick A.

Drugs used in Alzheimer's disease and neuroplasticity
pp. 4-15(12)
Authors: Allain H.; Bentue-Ferrer D.; Gandon J.-M.; Le Doze F.; Belliard S.

Acarbose: a review of US clinical experience
pp. 16-26(11)
Authors: Coniff R.; Krol A.

Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal Glucocorticoid for Allergic Rhinitis
pp. 27-38(12)
Authors: J.Davies R.; Nelson H.S.

Sedative effects of antihistamines: safety, performance, learning, and quality of life
pp. 39-55(17)
Author: Nolen T.M.

Neoadjuvant progesterone therapy for primary breast cancer: rationale for a clinical trial
pp. 56-61(6)
Author: Jatoi I.

Improved mealtime treatment of diabetes mellitus using an insulin analogue
pp. 62-72(11)
Authors: Anderson J.H.; Brunelle R.L.; Koivisto V.A.; Trautmann M.E.; Vignati L.; DiMarchi R.

On-demand therapy in gastroesophageal reflux disease: a comparison of the early effects of single doses of fast-dissolving famotidine wafers and ranitidine tablets
pp. 73-81(9)
Authors: Johannessen T.; Kristensen P.

Pharmaceutical economics & health policy
pp. 84-85(2)
Author: Sclar D.A.

International Expenditure Projections for pharmacotherapeutic advances in the treatment of HIV/AIDS
pp. 86-95(10)
Authors: Sclar D.A.; Robison L.M.; Skaer T.L.; Terriff C.M.; Garrison M.W.

Cost-effectiveness of long-term intrathecal morphine therapy for pain associated with failed back surgery syndrome
pp. 96-112(17)
Authors: de Lissovoy G.; Brown R.E.; Halpern M.; Hassenbusch S.J.; Ross E.

Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting
pp. 113-123(11)
Authors: Munroe W.P.; Kunz K.; Dalmady-Israel C.; Potter L.; Schonfeld W.H.

The added value of newer antipsychotics
pp. 126-127(2)
Author: Keks N.A.

Economic outcomes and costs in the treatment of schizophrenia
pp. 128-138(11)
Authors: Knapp M.; Kavanagh S.

Cost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone
pp. 139-147(9)
Author: Aronson S.M.

Impact of newer antipsychotics on outcomes in schizophrenia
pp. 148-158(11)
Author: Keks N.A.

Providing cost-effective therapy using pharmacoeconomic evaluations: the public sector approach
pp. 160-166(7)
Author: Finder S.

A Pharmacoeconomic Evaluation of the Use of Dexrazoxane in Preventing Anthracycline-Induced Cardiotoxicity in Patients with Stage IIIB or IV Metastatic Breast Cancer
pp. 167-184(18)
Authors: Bates M.; Lieu D.; Zagari M.; Spiers A.; Williamson T.